Ribeiro da Silva Joana, Proença Luísa, Rodrigues Adélia, Pinho Rolando, Ponte Ana, Rodrigues Jaime, Sousa Mafalda, Almeida Rita, Carvalho João
Department of Gastroenterology, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.
GE Port J Gastroenterol. 2018 Sep;25(5):236-242. doi: 10.1159/000485428. Epub 2017 Dec 21.
Obesity is an increasing worldwide problem associated with a vast number of comorbidities. Decreasing body weight by only 5-10% has been shown to slow and even prevent the onset of obesity-related comorbidities. Between pharmacological therapy and bariatric surgery a great variety of endoscopic techniques are available, the most common being intragastric balloon (IGB). The purpose of this study was to assess the safety, tolerance, and kinetics of IGBs in weight loss. The kinetics of weight loss were evaluated in 2 different contexts and phases: after the IGB's removal and after follow-up that varied between 6 and 12 months. Successful weight loss was defined as ≥10% weight loss after 6-12 months.
The study included 51 patients who had undergone Orbera® IGB placement between September 2014 and February 2016. Inclusion criteria were age between 18 and 65 years; body mass index (BMI) 28-35 with severe obesity-related disorders; or BMI 35-40. The IGB was removed 6 months later. All patients were followed for a minimum period of 6-12 months.
Of 51 patients, 16 were excluded (7 due to intolerance) and 35 patients entered the study, of which 83% were followed for more than 6-12 months. The average weight loss (WL) and % excess WL (%EWL) after 6 months of treatment were 11.94 kg and 42.16%, respectively. At 6-12 months, after removal of the IGB, the mean WL was 8.25 kg and %EWL was 30.27%. Nineteen patients attained a WL of ≥10% the baseline value at IGB removal and 12 maintained their weight below this threshold during the 6-12 following months.
After temporary IGB implantation in overweight or obese individuals, a WL that was ≥10% of weight at baseline was achieved in 54.3% and sustained at 6-12 months in 41.4% of participants. IGBs are an attractive intermediate option between diet and exercise programs and bariatric surgery. In general, IGB placement is a safe and well-tolerated procedure.
肥胖是一个日益严重的全球性问题，与大量合并症相关。体重仅减轻5%-10%已被证明可减缓甚至预防肥胖相关合并症的发生。在药物治疗和减肥手术之间，有多种内镜技术可供选择，最常见的是胃内球囊（IGB）。本研究的目的是评估IGB在减肥中的安全性、耐受性和减重动力学。在2种不同的情况和阶段评估体重减轻的动力学：IGB取出后以及6至12个月的随访后。成功减重定义为6至12个月后体重减轻≥10%。
本研究纳入了2014年9月至2016年2月期间接受奥贝拉®IGB置入术的51例患者。纳入标准为年龄在18至65岁之间；体重指数（BMI）为28-35且患有严重肥胖相关疾病；或BMI为35-40。6个月后取出IGB。所有患者至少随访6至12个月。
51例患者中，16例被排除（7例因不耐受），35例患者进入研究，其中83%的患者随访时间超过6至12个月。治疗6个月后的平均体重减轻（WL）和超重体重减轻百分比（%EWL）分别为11.94 kg和42.16%。在6至12个月时，IGB取出后，平均WL为8.25 kg，%EWL为30.27%。19例患者在IGB取出时体重减轻达到基线值的≥10%，12例患者在随后的6至12个月内体重维持在该阈值以下。
在超重或肥胖个体中临时植入IGB后，54.3%的参与者实现了基线体重≥10%的体重减轻，41.4%的参与者在6至12个月时体重减轻得以维持。IGB是饮食和运动计划与减肥手术之间有吸引力的中间选择。一般来说，IGB置入是一种安全且耐受性良好的手术。
